Pharmaceuticals
anyTarget: Drug Discovery Biotech
If you are a biotech company dealing with high R&D costs and slow wet-lab cycles — this project developed a predictive platform that can reduce cycle times and costs by at least 50%.
ATLAS · Project
Quantum-Powered Software Platform for Faster and Cheaper Drug Discovery
healthPilotedTRL 7
Imagine trying to find a specific key for a lock by trying millions of random keys by hand; that is how traditional drug discovery works. This project built a super-powered digital simulator that tests these keys on a computer using quantum physics. It lets scientists find the perfect match digitally before ever stepping into a lab.
By the numbers
50%
reduction in cycle times and cost
100
peer-reviewed papers grounding the technology
35
project portfolio target by 2027
18 months
target interval to generate a new candidate
The business problem
What needed solving
Drug discovery is currently too slow and expensive because it relies on physical lab experiments. Existing simulation tools lack the reliability and performance found in other engineering sectors.
The solution
What was built
An ultra-high resolution in silico drug design platform that integrates HPC and Quantum Processing Units (QPUs) for molecular dynamics.
Audience
Who needs this
Pharmaceutical R&D departmentsBiotech startupsComputational chemistry labsQuantum computing hardware providers
Business applications
Who can put this to work
Cloud Computing
enterpriseTarget: HPC Infrastructure Provider
If you are a cloud provider dealing with the need for specialized quantum and GPU workloads — this project developed a scalable platform that leverages CPU, GPU, and QPU hardware to run complex molecular simulations.
Healthcare
mid-sizeTarget: Clinical Research Organization
If you are a research organization dealing with the failure of drug candidates in early stages — this project developed an ultra-high resolution design tool to validate candidates in silico before they reach the clinic.
Frequently asked
Quick answers
How does this reduce the cost of drug development?
The platform replaces costly and laborious wet-lab experiments with in silico simulations, reducing cycle times and costs by at least 50%.
Can this handle industrial-scale drug screening?
Yes, the platform is designed for scalability to handle very large datasets, such as searching a chemical space of 10^60, using HPC and Quantum Processing Units.
What is the intellectual property basis for this technology?
The technology is grounded on over 100 peer-reviewed papers and two ERC grants, and has won the ATOS-Joseph Fourier prize.
What is the timeline for seeing clinical results?
The objective is for the first ATLAS-generated compound to reach the clinic by 2027.
How is the platform integrated with existing hardware?
It is designed to run on any hardware, whether on-premises or on the cloud, utilizing CPU, GPU, and QPU infrastructures.
Consortium
Who built it
The project is led by a single French SME, Qubit Pharmaceuticals. This lean structure suggests a highly focused, agile development process where 100% of the project is industry-driven, minimizing the gap between research and commercial application.
How to reach the team
Contact Qubit Pharmaceuticals in France regarding their ATLAS platform licensing.
Next steps
Talk to the team behind this work.
Request a technical deep-dive into the ATLAS quantum-simulation capabilities.
More in Health & Biomedical
See all Health & Biomedical projects →